Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Part A
- People who have been diagnosed with MGUS (a condition where abnormal proteins are found in the blood) with an abnormal result on a specific blood test called the free light chain ratio, or who have smouldering multiple myeloma (an early, symptom-free form of multiple myeloma)
- People who have not yet received any treatment for their condition
- People aged 18 years or older
- People who are able to understand and are willing to sign a consent form
- People who are planning to have their follow-up care at one of the participating medical centres
Part B
- People who have been diagnosed with a condition called systemic AL amyloidosis (a disease where abnormal proteins build up and damage organs)
- People who have not yet received any treatment for their condition
- People aged 18 years or older
- People who are able to understand and are willing to sign a consent form
- People who are planning to have their follow-up care at one of the participating medical centres
Who may not be able to join:
Part A
- People who have been diagnosed with a form of monoclonal gammopathy that is already causing symptoms
- People who have previously received treatment for any monoclonal gammopathy condition
Part B
- People whose amyloidosis is not the AL type
- People who have previously received treatment for AL amyloidosis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Assess proportion of patients with newly diagnosed AL identified through the biomarker-based screening of at-risk patient; Assess the proportion of patients with deep haematological response after frontline therapy (best response evaluation) in the new enhanced, contemporary, real-world series of AL patients enrolled during the study.; 3. Identify associations of clonal light chain features with different clinical features at baseline.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.